Abstract 167P
Background
Small cell lung cancer (SCLC) is the most aggressive subtype of lung cancer and is accompanied by frequent primary or acquired resistance to first-line treatment of chemo-immunotherapy resulting in very modest clinical benefit. Lurbinectedin is FDA-approved as a second-line treatment for SCLC.
Methods
In this study, we evaluated the effect of lurbinectedin on the immune microenvironment in SCLC in multiple immunocompetent mouse models and performed multi-color flow cytometry and bulk RNA sequencing.
Results
In multiple immunocompetent SCLC mouse models, lurbinectedin treatment remarkably enhanced the anti-tumor effect of PD-L1 blockade in tumors that show primary resistance to immunotherapy. Moreover, lurbinectedin caused significant tumor regression in mice that had developed acquired resistance to chemoimmunotherapy treatment demonstrating its efficacy as a superior second-line treatment. Lurbinectedin treatment caused micronuclei formation and activated the cGAS/STING pathway, induced the expression of Type I and II interferon pathways, and caused significant tumor infiltration of cytotoxic and memory/effector T-cells. Similarly, pro-inflammatory M1 type macrophages and dendritic cells were increased, while immunosuppressive M2 type macrophages and MDSC cells were dramatically decreased. Interestingly, lurbinectedin also led to significant induction of MHC class I in SCLC in vitro and in vivo models. Analysis of pre-and post-treatment clinical samples in patients with relapsed SCLCs validated the induction of MHC class I and interferon pathway genes. Finally, pre-and post-lurbinectedin treatment demonstrated a STING-mediated increase in damage-associated molecular patterns (DAMPs) associated with immunogenic cell death.
Conclusions
We provide the first mechanistic insight into the lurbinectedin-induced cGAS-STING activation and multimodal immune modulation in SCLC. Lurbinectedin is already approved as a second-line agent in SCLC. Hence, our findings highlight lurbinectedin as a potentially transformative therapy for SCLCs that have relapsed from chemoimmunotherapy treatment, paving the way for combination clinical trials with anti-PD-L1.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
14P - Integrated modelling of T cell repertoires to identify clonotype signatures of ICI response
Presenter: Juan Luis Melero
Session: Poster Display
16P - Exosomal PD-L1 and lactate predict clinical outcomes of PD-1 blockade combined with chemotherapy in advanced-stage gastric and gastroesophageal junction adenocarcinoma
Presenter: Yongshun Chen
Session: Poster Display
17P - Spatial Characteristics Associated with the Chemo and Immuno-treatment Response of Gastric Cancer Revealed by Multi-omics Analysis
Presenter: Gang Che
Session: Poster Display
18P - Association of DNA methylation profiles with pathologic complete response in early triple negative breast cancer patients receiving neoadjuvant chemoimmunotherapy
Presenter: Angelika Starzer
Session: Poster Display
19P - The prognostic value of soluble CD73 in advanced triple-negative breast cancer: an exploratory analysis of the SYNERGY trial
Presenter: Denis Zoë
Session: Poster Display
21P - Mass cytometry reveals a population of exhausted CD8+ T cells associated with durvalumab/tremelimumab/vinorelbine efficacy in advanced cervical cancer (iMOVIE).
Presenter: Alexandre Bertucci
Session: Poster Display
22P - Predictive value of Tertiary Lymphoid Structure in patients with mismatch repair deficient advanced/ recurrent endometrial cancer treated with Dostarlimab.
Presenter: Maria Kfoury
Session: Poster Display
23P - Circulating immune cells and activity of immune checkpoint inhibitors in metastatic renal cell carcinoma
Presenter: Ronan Flippot
Session: Poster Display
24P - Chromosome 3p-related gene alterations (GA) as biomarkers for immunocombinations in metastatic renal cell carcinoma (mRCC): a hypothesis-generating analysis
Presenter: Matteo Rosellini
Session: Poster Display